Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 221

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 221
---
 of annual new cases of Breast
Cancer in the female US population by age groups:

These are the numbers for the year 2025. For each year in the valuation we used and estimation of the total relevant population of that year based on estimations given by the United Nations Department of Economic and Social Affairs 6. We then used the distribution of new cancer cases by cancer stage at the time of discovery, as follows 7:

We assumed that the new developed drug would treat only cancer stages I – III.

Canada & Mexico 8, 9

distribution of new cancer cases
by cancer stage, :

5https://cancerstatisticscenter.cancer.org/estimates/new-cases

6https://population.un.org/wpp/downloads?folder=Probabilistic%20Projections&group=Population

7https://www.cdc.gov/united-states-cancer-statistics/publications/breast-cancer-stat-bite.html

8https://cancer.ca/en/cancer-information/cancer-types/breast/statistics

9https://gco.iarc.who.int/media/globocan/factsheets/populations/484-mexico-fact-sheet.pdf

10https://jamanetwork.com/journals/jamaoncology/fullarticle/2811796

11https://aacrjournals.org/cebp/article/30/7_Supplement/47/670936/Abstract-47-Survival-of-Breast-Cancer-in-Women

| Moore Financial Consulting |

| Telomir Pharmaceuticals, Inc.Valuation | November 2025Page 18 of 24 |

The above figures are based on the current adult populations in each of the geographical markets. The valuation is based on estimations of the future populations in these markets, as follows (New Treatable cases):

Market Share

Our assumptions regarding the market shares of each indication in all the markets are as follows:

Treatments: Schedule and Price

Our assumption regarding the eventual drugs sale prices is presented in the following table. Prices for AMD treatments are based on existing treatment list prices of branded products used for these indications nowadays. For Breast Cancer, we based ourselves on the current list prices of treatments that are close to actual treatments used nowadays. For further explanations regarding the benchmark used, please refer to the relevant appendix. Revenues are 70% of the List Prices (Gross to Net).

Upfront and Royalties

As mentioned, one of the main assumptions is that the Company will continue developing and testing the AMD and Breast